Early clinical experience with imatinib in COVID-19: Searching for a dual effect
Alejandro Morales‐Ortega, Luis Rivas, Begoña Frutos‐Pérez, Beatriz Jaenes‐Barrios, Ana Isabel Farfán‐Sedano, Carlos Javier García‐Parra, Belén Hernández‐Muniesa, Miguel Ángel Duarte‐Millán, Elena Madroñal‐Cerezo, Ana Ontañon, José Manuel Ruiz‐Giardín, Fernando Bermejo, Mario García‐Gil, Sonia Gonzalo‐Pascua, Juan San Martín, David Bello
Topics & Concepts
MedicineImatinibSofosbuvirTyrosine-kinase inhibitorTyrosine kinaseCoronavirus disease 2019 (COVID-19)FavipiravirNucleoside analogueOncologyImmunologyInternal medicineMyeloid leukemiaVirusCancerDiseaseRibavirinBiologyNucleosideBiochemistryHepatitis C virusReceptorInfectious disease (medical specialty)Immune Cell Function and InteractionChronic Myeloid Leukemia TreatmentsHematopoietic Stem Cell Transplantation